Send by FierceBiotech

Pfizer and Bristol Myers Squibb's blood thinner apixaban beat aspirin in a study that may open the door to a multi-billion dollar-a-year market to prevent [...]

Send by Moneycontrol.com

of clot preventer developed by Pfizer and Bristol-Myers called apixaban and Vertex Pharmaceuticals Inc's hepatitis C treatment telaprevir, Aitken said. [...]

Send by American Banking News

of Bristol-Myers (NYSE :BMY) from “Buy” to “hold” in a research note to investors on Tuesday, citing increased expectations for apixaban and ipilimumab. [...]

4 Mar 2010 Copenhagen, Denmark - The investigational anticoagulant apixaban (Bristol-Myers Squibb/Pfizer) is more effective than the dose of enoxaparin [...]

PRINCETON, NJ & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical [...]

11 Jun 2010 Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of [...]

31 Aug 2010 Researchers have prematurely terminated a clinical trial of an experimental blood thinner because the drug proved to be much better than [...]

Find out more about apixaban, dabigatran, and rivaroxaban on a Web site dedicated to information about new anticoagulation targets and single coagulation [...]

31 Aug 2010 The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in [...]

The oral factor Xa inhibitor apixaban has been found superior to enoxaparin in preventing venous thromboembolism after knee-replacement surgery, with similar rates of bleeding, in a randomized placebo-controlled phase III trial. [...]

Send by biz.yahoo.com

Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics [...]

Phase III Data Published in The Lancet also Demonstrate Comparable Rates of Bleeding with Apixaban Versus Enoxaparin Mar 4, 2010 - Apixaban, an oral anticoagula [...]

Send by Lisa LaMotta

?This was not a head-to-head trial comparing apixaban to warfarin,? write Sanford Bernstein analyst Tim Anderson in a note to clients on Tuesday. ?Rather, it was evaluating apixaban versus aspirin in patients at risk of stroke who were [...]

Send by TheStreet.com

Bristol-Myers (BMY) upgraded at Jefferies to Buy from Hold on increased expectations for apixaban and ipilimumab, and a low risk of losing US exclusivity [...]

Send by www.businessweek.com

Boehringer Ingelheim GmbH won U.S. approval to sell Pradaxa, beating drugmakers including Bayer AG and Johnson & Johnson to the market with the first rival to the half-century-old blood thinner warfarin. [...]

Send by Liz Jones Hollis

AVERROES trial terminated early: apixaban associated with "important" relative risk reduction for stroke and systemic embolism in AF Date : 31 Aug 2010 The phase 3 AVERROES (Apixaban Versus Read more [...]

??????????? AVERROES, ?????????? ????????????? ? ????????????? ?? apixaban (Pfizer/Bristol-Myers Squibb) ? ??????? ??? ???????? ? ?????????? ???????, ?? ?????????? ??????????, ???? ???? ????? ?????? ?? ????????? ??????? ???????? [...]

For investors who have been asking themselves whether medium-size pharmaceutical companies can survive in an industry that has had recent mega-mergers, the answer seems to be yes. At least for Bristol-Myers Squibb. The company’s experimental anticoagulant drug apixaban worked better than aspirin in [...]

Send by Michael Rud Lassen, Gary E Ras

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. By - Dr Michael Rud Lassen MD, Gary E Raskob PhD, Alexander Gallus MD, Graham [...]

Send by Larry Husten

The phase 3 AVERROES trial comparing apixaban to aspirin in 5600 AF patients unable to take warfarin has been stopped early by the Data Monitoring Committee after a predefined interim analysis found a significant reduction in stroke and [...]

Send by Wendy Diller

Bristol-Myers/Pfizer's anticoagulant apixaban bests aspirin in preventing stroke in certain patients - Pharma industry agreements with Swedish government result in voluntary price reductions - Reckitt Benckiser receives FDA approval for [...]

Pfizer and Bristol-Myers Squibb's apixaban has suffered a setback in trials against So Apixaban was not "better" then enoxaparin. This means it's as good [...]

Send by bowersc

In ADVANCE-2 3057 patients undergoing elective total knee replacement were randomised to oral apixaban 2.5mg twice a day, started 12 to 24 hours after surgery, or 40mg enoxaparin daily, started 12 hours before surgery. [...]

Send by Jack Shu

Next week, two rival anti-clotting pills are set to release their data. Bristol-Meyer's apixaban and Bayer's Xarelto are in a race to replace warfarin, the. [...]

Cnews health The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment [...]